Oral Aleniglipron Reduced Weight at 36 Weeks - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Oral Aleniglipron Reduced Weight at 36 Weeks

In a phase 2b trial, the highest dose produced an estimated 12% mean weight reduction vs 1% with placebo, although gastrointestinal adverse events were common.

  • By

  • Kathryn Wighton

  • July 16, 2026

  • 6 min

Share

Objective:

To evaluate the efficacy of once-daily aleniglipron in reducing body weight in adults with obesity or overweight without diabetes.

Approach:
  • Trial Design: A randomized phase 2b double-blind, placebo-controlled trial (ACCESS) conducted at 38 US sites.
  • Participants: 406 adults screened; 230 randomly assigned to aleniglipron (45 mg, 90 mg, 120 mg) or placebo.
  • Endpoints: Primary endpoint was percentage change in body weight from baseline to week 36.
Key Findings:
  • Atwek36simdnboyghcl945102prju8fv
Interpretation:

The study demonstrated significant weight loss with aleniglipron compared to placebo, with a favorable safety profile despite common gastrointestinal side effects.

Limitations:
  • EnrolmtxcusivyadpWhgzbf
Conclusion:

Aleniglipron was associated with significant weight loss in adults with obesity or overweight without diabetes.

Sources:

Original Source(s)

Oral Aleniglipron Reduced Weight at 36 Weeks

  • by Kathryn Wighton

  • July 16, 2026

Related Content

FDA flags potential cardiac risk with evenamide

Four deaths among evenamide-treated patients prompted FDA concerns about possible fatal arrhythmias, although a causal link remains unconfirmed.

Anticoagulant recalled over life-threatening risk

Contamination in 22 lots of the injection may cause pulmonary embolism or vascular occlusion; no related adverse events reported.

Misleading AI summaries may alter recall

Participants exposed to inaccurate postevent summaries were less likely to correctly remember key details from videos they had previously watched.